These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 229592)

  • 1. Effect of primary and recurrent cytomegalovirus infections upon graft and patient survival after renal transplantation.
    Whelchel JD; Pass RF; Diethelm AG; Whitley RJ; Alford CA
    Transplantation; 1979 Dec; 28(6):443-6. PubMed ID: 229592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of the prevalence and symptomatology of cytomegalovirus infection in renal transplant recipients.
    Chatterjee SN; Jordan GW
    Transplantation; 1979 Dec; 28(6):457-60. PubMed ID: 229594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection: a quantitative prospective study of three hundred twenty consecutive renal transplants.
    Marker SC; Howard RJ; Simmons RL; Kalis JM; Connelly DP; Najarian JS; Balfour HH
    Surgery; 1981 Jun; 89(6):660-71. PubMed ID: 6264640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year experience with human cytomegalovirus infections in heart transplant recipients.
    Grossi P; Revello MG; Minoli L; Percivalle E; Zavattoni M; Poma G; Martinelli L; Gerna G
    J Heart Transplant; 1990; 9(6):712-9. PubMed ID: 2177498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The problem of cytomegalovirus infection in renal allograft recipients.
    Kurtz JB; Thompson JF; Ting A; Pinto A; Morris PJ
    Q J Med; 1984; 53(211):341-9. PubMed ID: 6091169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of presence of HBs antigen and anti-hepatitis C virus and anti-cytomegalovirus antibodies on transplanted kidney survival.
    Sieńko J; Wiśniewska M; Ciechanowski K; Rózański J; Domański L; Myslak M; Kamiński M; Sulikowski T; Pabisiak K; Romanowski M; Mizerski A; Tejchman K; Nowacki M; Ostrowski M; Bohatyrewicz R
    Transplant Proc; 2006; 38(1):136-8. PubMed ID: 16504685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of viral infections on renal transplants and their recipients.
    Warrell MJ; Chinn I; Morris PJ; Tobin JO
    Q J Med; 1980; 49(194):219-31. PubMed ID: 6254109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
    Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
    Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infection blocks the beneficial effect of pretransplant blood transfusion on renal allograft survival.
    Andrus CH; Betts RF; May AG; Freeman RB
    Transplantation; 1979 Dec; 28(6):451-6. PubMed ID: 229593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
    Burak KW; Kremers WK; Batts KP; Wiesner RH; Rosen CB; Razonable RR; Paya CV; Charlton MR
    Liver Transpl; 2002 Apr; 8(4):362-9. PubMed ID: 11965581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
    Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
    Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients.
    Leroy F; Sechet A; Abou Ayache R; Thierry A; Belmouaz S; Desport E; Bauwens M; Bridoux F; Touchard G
    Transplant Proc; 2006 Sep; 38(7):2324-6. PubMed ID: 16980080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural course of cytomegalovirus infection and disease in renal transplant recipients.
    Hartmann A; Sagedal S; Hjelmesaeth J
    Transplantation; 2006 Jul; 82(2 Suppl):S15-7. PubMed ID: 16858268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgM antibody detection of ppUL80A and ppUL32 by immunoblotting: an early parameter for recurrent cytomegalovirus infection in renal transplant recipients.
    Kraat YJ; Stals FS; Christiaans MH; Lazzarotto T; Landini MP; Bruggeman CA
    J Med Virol; 1996 Mar; 48(3):289-94. PubMed ID: 8801292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent cytomegalovirus disease in solid-organ transplant recipients.
    Falagas ME; Snydman DR
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):34-7. PubMed ID: 7482815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function.
    Petrakopoulou P; Kübrich M; Pehlivanli S; Meiser B; Reichart B; von Scheidt W; Weis M
    Circulation; 2004 Sep; 110(11 Suppl 1):II207-12. PubMed ID: 15364864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of rapid methods of detecting cytomegalovirus in the blood of renal transplant recipients in relation to patient and graft survival.
    Eriksson BM; Wirgart BZ; Claesson K; Tufveson G; Magnusson G; Tötterman T; Grillner L
    Clin Transplant; 1996 Dec; 10(6 Pt 1):494-502. PubMed ID: 8996769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
    Doyle AM; Warburton KM; Goral S; Blumberg E; Grossman RA; Bloom RD
    Transplantation; 2006 Apr; 81(8):1106-11. PubMed ID: 16641594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.